Last reviewed · How we verify
prednisolone + mabthera
Prednisolone is a corticosteroid that suppresses the immune system, while Mabthera (rituximab) is a monoclonal antibody that targets CD20 on B cells.
Prednisolone is a corticosteroid that suppresses the immune system, while Mabthera (rituximab) is a monoclonal antibody that targets CD20 on B cells. Used for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.
At a glance
| Generic name | prednisolone + mabthera |
|---|---|
| Also known as | mabthera equals Rituximab |
| Sponsor | Copenhagen University Hospital at Herlev |
| Drug class | Corticosteroid + Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Prednisolone works by inhibiting the production of inflammatory cytokines, thereby reducing inflammation and immune response. Mabthera, on the other hand, binds to CD20 on B cells, marking them for destruction and reducing B cell-mediated immune responses.
Approved indications
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
Common side effects
- Infections
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (PHASE2)
- Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy (PHASE2)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma (PHASE3)
- A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prednisolone + mabthera CI brief — competitive landscape report
- prednisolone + mabthera updates RSS · CI watch RSS
- Copenhagen University Hospital at Herlev portfolio CI